EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access · CC BY-NC 4.0

ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma

Isabel Arrillaga-Romany iD, Andrew Lassman, Susan L McGovern, Sabine Mueller, Burt Nabors, Martin van den Bent, Michael A Vogelbaum, Joshua E Allen, Allen S Melemed, Rohinton S Tarapore, Patrick Y Wen, Timothy Cloughesy

Neuro-Oncology · 03.05.2024 · 26 (Supplement_2) · S173-S181

DOI: 10.1093/neuonc/noae031 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Neuro-Oncology, online erschienen am 06.03.2024. Verfasst von Isabel Arrillaga-Romany und 11 weiteren Autor:innen. Beteiligte Einrichtung: Mass General Cancer Center, Neuro-Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Glioma, Brain Neoplasms, Mutation. Die Arbeit wurde bisher 76-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Chimerix.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

H3 K27M-mutant diffuse glioma primarily affects children and young adults, is associated with a poor prognosis, and no effective systemic therapy is currently available. ONC201 (dordaviprone) has previously demonstrated efficacy in patients with recurrent disease. This phase 3 trial evaluates ONC201 in patients with newly diagnosed H3 K27M-mutant glioma.

Methods

ACTION (NCT05580562) is a randomized, double-blind, placebo-controlled, parallel-group, international phase 3 study of ONC201 in newly diagnosed H3 K27M-mutant diffuse glioma. Patients who have completed standard frontline radiotherapy are randomized 1:1:1 to receive placebo, once-weekly dordaviprone, or twice-weekly dordaviprone on 2 consecutive days. Primary efficacy endpoints are overall survival (OS) and progression-free survival (PFS); PFS is assessed by response assessment in neuro-oncology high-grade glioma criteria (RANO-HGG) by blind independent central review. Secondary objectives include safety, additional efficacy endpoints, clinical benefit, and quality of life. Eligible patients have histologically confirmed H3 K27M-mutant diffuse glioma, a Karnofsky/Lansky performance status ≥70, and completed first-line radiotherapy. Eligibility is not restricted by age; however, patients must be ≥10 kg at time of randomization. Patients with a primary spinal tumor, diffuse intrinsic pontine glioma, leptomeningeal disease, or cerebrospinal fluid dissemination are not eligible. ACTION is currently enrolling in multiple international sites.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaBrain NeoplasmsMutationHumansDouble-Blind MethodAdultMaleFemaleHistonesAdolescentChildYoung AdultPrognosisSurvival RateQuality of LifeMiddle AgedFollow-Up StudiesAged

Stichwörter der Autor:innen

H3 K27MONC201Phase 3diffuse gliomadordaviprone

Substanzen

Histones

Autor:innen und Institutionen

  • Mass General Cancer Center, Neuro-Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Columbia University Vagelos College of Physicians and Surgeons, Herbert Irving Comprehensive Cancer Center, New York-Presbyterian Hospital, New York City, New York, USA.
  • Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California, USA.
  • Department of Neuro-Oncology, University of Alabama at Birmingham, Birmingham, Alabama, USA.
  • Brain Tumor Center at Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands.

ORCID-Profile: Isabel Arrillaga-Romany

Förderung

  • NCI NIH HHS
  • Chimerix

Zitieren

APA

Arrillaga-Romany, I., Lassman, A., McGovern, S. L., Mueller, S., Nabors, B., van den Bent, M., Vogelbaum, M. A., Allen, J. E., Melemed, A. S., Tarapore, R. S., Wen, P. Y., & Cloughesy, T. (2024). ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma. Neuro-Oncology, 26(Supplement_2), S173-S181. https://doi.org/10.1093/neuonc/noae031

Vancouver

Arrillaga-Romany I, Lassman A, McGovern SL, Mueller S, Nabors B, van den Bent M, et al. ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma. Neuro-Oncology. 2024;26(Supplement_2):S173-S181. doi:10.1093/neuonc/noae031

BibTeX
@article{ArrillagaRomany2024,
  author = {Arrillaga-Romany, Isabel and Lassman, Andrew and McGovern, Susan L and Mueller, Sabine and Nabors, Burt and van den Bent, Martin and Vogelbaum, Michael A and Allen, Joshua E and Melemed, Allen S and Tarapore, Rohinton S and Wen, Patrick Y and Cloughesy, Timothy},
  title = {ACTION: a randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma},
  journal = {Neuro-Oncology},
  year = {2024},
  volume = {26},
  number = {Supplement_2},
  pages = {S173--S181},
  doi = {10.1093/neuonc/noae031}
}
Kostenlos starten →